Senseera is a cutting-edge biotechnology company revolutionizing precision medicine through its proprietary cfChIP-seq liquid biopsy platform. Founded by world-renowned computational biologist Professor Nir Friedman, Senseera integrates advanced molecular biology and computational expertise to extract cell-specific gene expression data from blood-derived DNA. This innovative technology enables unparalleled insights into dynamic cell states and pathways, providing high-resolution molecular data for disease detection, monitoring, and treatment response.  Backed by leading investors such as Lightspeed VC and the Israel Innovation Authority, Senseera boasts a robust infrastructure, including a fully automated lab with ISO 15189 certification and a unique atlas of over 20,000 annotated human samples. This extensive dataset supports collaborations with pharma and biotech partners, advancing biomarker discovery, clinical trial optimization, and novel diagnostic applications. Senseera’s mission is to transform healthcare by delivering actionable insights for a wide range of diseases, making precision medicine more effective and accessible globally.